The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board (PPSB) is a pre-competitive space where researchers share scientific progress and findings. Originally led by the Foundation for the National Institutes on Health (FNIH), the Alzheimer’s Association now leads the convening of this forum.
Background
The ADNI-PPSB serves as an independent, open, and pre-competitive forum in which all private sector and not-for-profit partners in the ADNI can collaborate, share information, and offer scientific and private-sector perspectives and expertise on issues relating to ADNI.
“Our goal in convening the ADNI-PPSB is to provide global industry experts a platform to collaborate, and allow for projects to emerge and crystallize from ADNI-PPSB members."
Chris Weber, Director, Corporate Initiatives, Alzheimer's Association
The forum's newest workgroup, ADNI Diversity, Equity & Inclusion, is addressing issues of diversity, equity and inclusion, particularly in the context of recruiting a more diverse and representative group of participants for the study, which is a high priority of ADNI4. The focus will be on groups that are historically under-represented, such as Black Americans/African-Americans, Hispanic Americans/Latinx Americans, Asian Americans and Pacific Islanders, American Indians, and people with less than a high school education.
The ADNI-PPSB has several opportunities to get involved, including:
- ADNI PET Endpoints workgroup
- ADNI Diversity, Equity & Inclusion workgroup
- ADNI Biomarkers & Biofluids workgroup
- ADNI Clinical Endpoints workgroup
Alzheimer’s Disease Neuroimaging Initiative
The
ADNI, a landmark partnership and study that for years has profoundly influenced our understanding of Alzheimer’s disease (AD), is identifying the earliest changes in brain structure and function that signal its onset and progression of AD.
The study has been led by the National Institute on Aging with support from the FNIH and more than 30 private-sector organizations since its launch in 2004, including the Alzheimer’s Association. ADNI has gone through several peer-reviewed renewals since ADNI1, in 2014, with ADNI-GO and ADNI2. ADNI3 partnership and study was launched in 2016. The new grant will fund a five-year extension of the study, termed ADNI4, which began in September 2022. Importantly, and new in this stage of the study, between 50 and 60% of participants will be from populations historically under-represented in medical/scientific research.
Partners
Get involved
If companies are interested in learning more about the ADNI-PPSB and the workgroups available, please contact:
Chris Weber
Director, Global Science Initiatives
cweber@alz.org
Tommy Morris
Senior Director, Corporate Initiatives
tomorris@alz.org